Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2020
October 2020, Vol 11, No 5
October 2020, Vol 11, No 5
Adjuvant Immunotherapy with Ipilimumab Improves Survival in Patients with Stage III Melanoma in the Real-World Setting
By
Phoebe Starr
Melanoma
October 2020, Vol 11, No 5
A real-world analysis showed that adjuvant immunotherapy in patients with stage III melanoma improved survival, but that only approximately 33% of eligible patients received such adjuvant therapy after ipilimumab (Yervoy) was approved by the FDA for this indication.
Read Article
Drug Manufacturers’ Response to the Pandemic
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
Leading global drug manufacturers have been called on to respond to the COVID-19 pandemic in a myriad of ways; several of their executives discussed those responses in a mid-August webcast from the Association for Value-Based Cancer Care.
Read Article
Impact of COVID-19 on Economic Trends in Oncology
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
Patients with cancer and cancer treatment dynamics continue to bounce back toward baseline as of late summer 2020, reported experts at the Association for Value-Based Cancer Care August 20 webcast, which focused on economic trends in cancer care during the COVID-19 pandemic.
Read Article
Washington and Public Policy Update During COVID-19
AVBCC COVID-19 Webcast Series Coverage
October 2020, Vol 11, No 5
What are the practical implications of a flurry of recent healthcare-related actions taken by Congress, the Centers for Medicare & Medicaid Services (CMS), and the White House? In summary, “Some can happen, some will take significant effort, but most are just political grandstanding as we get closer to the election,” said Jayson Slotnik, JD, MPH, Partner, Health Policy Strategies, Bethesda, MD, and moderator of the mid-August webcast from the Association for Value-Based Cancer Care.
Read Article
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
By
Phoebe Starr
ESMO 2020 Highlights
October 2020, Vol 11, No 5
PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and
BRCA1/2
mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and
BRCA1
or
BRCA2
, and to a lesser extent
ATM
mutations, according to the final analysis of the phase 3 PROfound trial.
Read Article
Cabozantinib plus Nivolumab Combination Potential New First-Line Option for Patients with Advanced Renal-Cell Carcinoma
By
Phoebe Starr
ESMO 2020 Highlights
October 2020, Vol 11, No 5
The combination of cabozantinib (Cabometyx), a second-generation tyrosine kinase inhibitor (TKI), plus nivolumab (Opdivo), an immune checkpoint inhibitor, significantly improved overall survival (OS) and doubled the objective response rates (ORR) compared with the current standard, sunitinib (Sutent), in treatment-naïve patients with advanced renal-cell carcinoma (RCC), according to the results of the phase 3 CheckMate-9ER clinical trial. The results were presented at the 2020 European Society for Medical Oncology virtual meeting and were featured at the meeting press conference.
Read Article
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
By
Phoebe Starr
ESMO 2020 Highlights
October 2020, Vol 11, No 5
Nivolumab (Opdivo) is forging a new role in gastroesophageal cancers, according to results of 3 phase 3 clinical trials indicating that nivolumab as first-line therapy or adjuvant therapy can improve survival in patients with gastric and gastroesophageal junction (GEJ) cancer. These results are a “paradigm shift” for these patients, but questions remain, suggested several experts who discussed these results at the 2020 of the European Society for Medical Oncology (ESMO) virtual meeting.
Read Article
Can We Lower the Cost of Cancer Care?
By
Wayne Kuznar
Value-Based Care
October 2020, Vol 11, No 5
Value-based drug purchasing, better coordination of care delivery, and earlier institution of palliative care were among the measures to lower the cost of cancer care that were suggested during a panel discussion at the 2020 virtual National Comprehensive Cancer Network (NCCN) Oncology Policy Summit. The discussion was moderated by Clifford Goodman, PhD, Senior Vice President, Comparative Effectiveness Research, the Lewin Group.
Read Article
Personalized Vaccine plus Immune Checkpoint Inhibitor a Promising Approach to Cancer
By
Phoebe Starr
Immunotherapy
October 2020, Vol 11, No 5
Many cancer vaccines have been studied, but thus far the search has been unsuccessful. Results from a new study suggest that the combination of a messenger (mRNA)-based personalized cancer vaccine (known as RO7198457) plus the PD-L1 inhibitor atezolizumab (Tecentriq) shows promise for the treatment of advanced cancer. The results of the phase 1b clinical trial were presented at the 2020 AACR virtual annual meeting.
Read Article
Pembrolizumab New Standard of Care for Relapsed or Refractory Classical Hodgkin Lymphoma
By
Phoebe Starr
Lymphoma
October 2020, Vol 11, No 5
Treatment with the PD-1 inhibitor pembrolizumab (Keytruda) significantly extended progression-free survival (PFS) in patients with classical Hodgkin lymphoma compared with standard treatment with brentuximab vedotin (Adcetris), according to the results of the phase 3 KEYNOTE-204 clinical trial reported at the ASCO 2020 virtual annual meeting.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma